SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response

Poor clinical outcomes in cancer can often be attributed to inadequate response to chemotherapy. Strategies to overcome either primary or acquired chemoresistance may ultimately impact on patients' survival favourably. We previously showed that lower levels of SPARC were associated with therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheetham, S, Tang, M J, Mesak, F, Kennecke, H, Owen, D, Tai, I T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410109/
https://www.ncbi.nlm.nih.gov/pubmed/18458674
http://dx.doi.org/10.1038/sj.bjc.6604377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410109/
https://www.ncbi.nlm.nih.gov/pubmed/18458674
http://dx.doi.org/10.1038/sj.bjc.6604377

Ejemplares similares